Stock in Focus: This Multibagger Micro-Cap Company Achieves Major Milestone with UNICEF; details inside!

The stock is up by 70 per cent in just 1 year and generated multibagger returns of 1,280 per cent in 5 years.

Venus Remedies Ltd has achieved a major accomplishment by winning a prestigious award from UNICEF for their antibiotic, Ceftriaxone lgm. This award follows their previous success of obtaining GMP (Good Manufacturing Practices) approval from UNICEF, solidifying their commitment to exceptional quality. UNICEF's decision to select Venus Remedies highlights their unwavering dedication to excellence in healthcare. Their Ceftriaxone lgm product has not only met but exceeded rigorous quality standards, showcasing their commitment to producing top-tier pharmaceutical solutions. This recognition not only emphasizes the superior quality of their product but also strengthens their position as a trusted partner in global health initiatives.

Looking ahead, Venus Remedies remains committed to upholding the highest standards of quality and dedication. They ensure their products significantly contribute to the well-being of communities worldwide. With this dedication, they stay true to their mission of advancing global health through innovation and excellence in the pharmaceutical industry.

Also Read: Penny stock at Rs 1.87 hits 52-week high: Company signs an MoU worth Rs 25,00,00,000 with Felix Industries for renewable energy; details inside!

Venus Remedies Ltd, founded in 1989, is a research-driven pharmaceutical company and a leading manufacturer of injectable medications, particularly meropenem antibiotics. They offer a broad range of pharmaceuticals across various therapeutic areas like antibiotics, oncology, pain management, and wound care. With over 800 marketing approvals globally and a product portfolio exceeding 90 items, Venus Remedies includes innovative formulations like injectables, tablets, and topical medications. Their product basket is divided into two categories: Research Products, which include brand names like Elores, Taxedol, and Achnil, and Generic Products, encompassing medications like Aceclofenac, Metformin, and Amikacin.

Today, Venus Remedies Ltd.’s shares surged 2.35 per cent to Rs 385 per share from the prior close of Rs 376.15. The stock holds a PE of 14.03x compared to the sectoral PE of 31x with a market capitalization of over Rs 500 crore.

The stock is up by 70 per cent in just 1 year and generated multibagger returns of 1,280 per cent in 5 years. Investors should keep an eye on this micro-cap stock.

Disclaimer: The article is for informational purposes only and not investment advice.